Drugs / WT1 mRNA-loaded dendritic cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02649582 | Dec 2015 → Jul 2027 expected | brain glioblastoma | University Hospital, Antwerp | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WT1 mRNA-loaded dendritic cells | “In addition to standard of care consisting of adjuvant chemoradiation with temozolomide and temozolomide maintenance patients will receive an intradermal vaccination with...” NCT02649582 ↗ |
| Modality | Cell therapy | “The dendritic cell therapy product will be generated and administered in the Antwerp University Hospital” NCT02649582 ↗ |